Back to Journals » Neuropsychiatric Disease and Treatment » Volume 5

Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease

Authors Puangthong U, Hsiung GR

Published 30 October 2009 Volume 2009:5 Pages 553—561

DOI https://doi.org/10.2147/NDT.S5021

Review by Single-blind

Peer reviewer comments 4


Umamon Puangthong, Ging-Yuek Robin Hsiung

Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

Abstract: Alzheimer’s disease is the most common cause of dementia in older adults. The clinical features include progressive memory decline as well as cognitive deficits with executive dysfunction, language, visual perceptual difficulties, apraxia and agnosia. During the moderate to severe stage of the disease, there is a major decline in memory and function, while neuropsychiatric disturbances often emerge and patients become difficult to manage. These distressing symptoms increase caregiver burden and add to the direct costs of care of the patients. Any improvements in patient function and behavioral symptoms can reduce caregiver burden. Memantine has been available for a number of years in Europe and in North America. In this article, we examine the pharmacological rationale for its use, and the current clinical evidence for its efficacy and long-term effectiveness in the management of cognitive and behavioral symptoms in moderate to severe stages of Alzheimer’s disease.

Keywords: memantine, Alzheimer’s disease, dementia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]